https://www.selleckchem.com/pr....oducts/Rapamycin.htm
5 (95% CI 11.76-21.32) months compared to 11.3 (95% CI 9.86-15.51) months in CCL5 ; hazard ratio 1.95 (95% CI 1.04-8.65; p = 0.037). CCL5 is an independent prognostic biomarker in LAPC. Given the known role of CCL5 in tumour invasion, metastasis and the induction of an immunosuppressive micro-environment, targeting of CCL5-mediated pathways may offer therapeutic potential in pancreatic cancer. The SCALOP trial was registered with ISRCTN, number 96169987 (registered 29 May 2008). The SCALOP trial was registered with ISRCTN, number 9616
Like
Comment
Share
